Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

The most central findings in both GH deficiency in adults and the metabolic syndrome are abdominal/visceral obesity and insulin resistance.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, men only.

Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

Body fat was assessed from total body potassium, and abdominal sc and visceral adipose tissue was measured using computed tomography.

The glucose disposal rate (GDR) was measured during an euglycemic, hyperinsulinemic glucose clamp.

What Was Measured

PubMed files the paper under topics including Adipose Tissue, Blood Pressure, Body Composition, Diastole, Glucose, Hormones and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in people with low blood pressure and orthostatic hypotension.

The publication is from 1997 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Low blood pressure and orthostatic hypotension research.